Carol Ashe has been appointed to the Aptose Biosciences (NASDAQ: [[ticker:APTO]]) board of directors. Ashe is the chief business officer of the New York Genome Center, a nonprofit academic research institution. Ashe’s appointment was part of LifeSci Advisor’s “Board Placement Initiative,” a program developed to improve the diversity of corporate boards. The program was created after the New York-based investor relations consultancy drew scorn for hiring scantily clad women to attend its cocktail party during the 2016 J.P. Morgan conference in San Francisco. LifeSci Advisors says Ashe is the 15th woman placed on a corporate board through its program. Toronto-based Aptose’s lead drug, APTO-253, is in early stage testing as a treatment for blood cancers.
